BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Nov. 26, 2002
View Archived Issues
FDA requests additional animal study before lifting Vasomax clinical hold
Read More
Drug pipeline for bipolar disorder
Read More
MLN-2704 enters phase I in androgen-independent prostate cancer
Read More
Elan completes sale of Abelcet to Enzon
Read More
FDA panel recommends approval of rhBMP for open long bone fractures
Read More
Positive opinion for Levitra in E.U.
Read More
New inhibitors of GSK-3 and/or ROCK kinase under study at Vertex
Read More
AstraZeneca presents novel cannabinoid CB2 agonists as potential analgesic agents
Read More
Japan Energy and Sumitomo describe new immunomodulators for cancer and other disorders
Read More
Novel Src kinase inhibitors in early development at AstraZeneca
Read More
Series of vascular damaging agents and their use in cancer, arthritis, diabetes, etc.
Read More
Bayer claims Raf kinase inhibitors with utility in cancer
Read More
Inhibitor of novel cancer target is selectively cytotoxic to tumor cells
Read More
Positive opinion issued in E.U. for Hepsera
Read More
PX-478, the lead in a novel class of HIF-1 inhibitors with excellent antitumor activity
Read More
Antiangiogenic/antimetastatic peptide completes preclinical evaluation
Read More
Ethypharm and Conba enter into strategic alliance
Read More
NeuroSearch and GlaxoSmithKline target depression
Read More
Probiodrug and Synt:em to apply Pep:trans technology for the treatment of CNS diseases
Read More
Additional primary endpoint data released from phase III Aldurazyme study
Read More
New Backgrounder published -- Rhinovirus posted November 20, 2002
Read More